Yaung‐Kaung Shen

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

Andrew Blauvelt, Kim Papp, C.E.M. Griffiths et al. · Journal of the American Academy of Dermatology · 2017 · 860 citations · Full text

Medicine, Dermatology, Pharmacotherapy +17

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

Kristian Reich, April W. Armstrong, Peter Foley et al. · Journal of the American Academy of Dermatology · 2017 · 731 citations · Full text

Medicine, Dermatology, Pharmacotherapy +15

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

Christopher T. Ritchlin, Proton Rahman, Arthur Kavanaugh et al. · Annals of the Rheumatic Diseases · 2014 · 658 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial

Alice B. Gottlieb, Alan Menter, Alan M. Mendelsohn et al. · The Lancet · 2009 · 583 citations

Medicine, Clinical Sciences, Immunology +15

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis

Kenneth B. Gordon, Kristina Callis Duffin, Robert Bissonnette et al. · New England Journal of Medicine · 2015 · 298 citations · Full text

Medicine, Dermatology, Pharmacotherapy +15